-
140 OTC drugs sold over 100 million!
Time of Update: 2022-01-26
com, there are 4 traditional Chinese medicine OTC products with sales expected to exceed 1 billion yuan in 2021 in Chinese urban physical pharmacy terminals: Ganmaoling Granules and Jianwei Xiaoshi Tablets have increased sales compared with 2020, while Banlangen The sales of Granules and Lianhua Qingwen Capsules rose sharply in 2020 due to the epidemic, and returned to normal levels in 2021 .
-
202 large varieties have met the conditions for national picking (list attached)
Time of Update: 2022-01-26
com, in 2020, the sales of tenofovir alafenamide in China's public medical institutions exceeded 370 million yuan, a year-on-year increase of 860.
-
Vigorously developing the traditional Chinese medicine industry has become a long-term plan for various regions
Time of Update: 2022-01-26
Analysts said that the market size of China's traditional Chinese medicine industry can continue to grow rapidly, in addition to being affected by the improvement of people's living standards and the continuous increase in demand, it is mainly due to the support and guidance of domestic favorable policies and the response from various places .
-
Generic drug of Shengshi Taike Teriflunomide approved for the treatment of multiple sclerosis
Time of Update: 2022-01-26
According to the priority review announcement of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, the approved indication for this drug is relapsing multiple sclerosis .
Retrieved Jan 5, 2022, from https:// Blockbuster | Aubajie®—the first oral drug for multiple sclerosis approved in China.
-
13 pharmaceutical companies disclosed annual report forecasts, 5 expected to double their net profit
Time of Update: 2022-01-26
Judging from the growth rate of net profit in the annual report, among the listed pharmaceutical companies whose annual reports are positive, 5 companies are expected to increase their net profit by more than 100% year-on-year, including Hualan, Yanan Bikang, Kaipu Bio, Mingde Bio, and Zhongsheng.
-
In 2021, 7 vaccines in China will be approved for use and 2 vaccines will be included in the global emergency use list
Time of Update: 2022-01-26
The reporter learned from the China 2022 National Science and Technology Work Conference held in Beijing on the 6th that new progress will be made in China's scientific and technological anti-epidemic in 2021, 14 vaccines have been approved for Phase III clinical trials, 7 vaccines have been approved for use, 2 The vaccine was included in the global emergency use list .
-
In 2022, what new trends will there be in the development of domestic innovative drugs?
Time of Update: 2022-01-26
With the help of policies and the efforts of major pharmaceutical companies, the number of domestic innovative drugs approved has been increasing in recent years .
-
The benefits of traditional Chinese medicine innovation are coming one after another!
Time of Update: 2022-01-26
Highlight the key role of human experience The "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine" issued in October 2019 put forward the requirements of the "three-in-one" review evidence system .
-
May 2022!
Time of Update: 2022-01-26
On January 6, the Shanghai Sunshine Pharmaceutical Purchasing Network released the "Notice on Announcement of the First-Year Agreement Purchase Volume of National Centralized Drug Purchasing (Insulin
-
The price of Chinese medicinal materials needs to be vigilant
Time of Update: 2022-01-26
The following is the author's specific analysis of the winning products and their raw material guarantee capabilities:01 Bid-winning products gather in leading companies01 Bid-winning products gather in leading companiesFigure 1: Proportion of winning bidders in the production enterprises of this variety (part)Judging from the proportion of successful bidders: Ginkgo biloba leaves and Salvia miltiorrhiza injections have significantly improved their supply concentration after centralized procurement .
-
A batch of medical institutions that illegally used traditional Chinese medicine injections were severely punished by the Medical Insurance Bureau!
Time of Update: 2022-01-26
In addition, medical institutions that use traditional Chinese medicine injections that are restricted to second-level hospitals and above due to violations include:Suichuan County Dayen Town Central Health Center and Dakeng Township Health Center illegally used Xiangdan injection, Qingkailing injection, Shengmai injection, etc.
-
Dizhe Pharmaceuticals DZD8586 obtained the approval notice for drug clinical trials from the State Food and Drug Administration
Time of Update: 2022-01-26
DZD8586 is an oral, highly selective, small molecule targeted drug that can penetrate the blood-brain barrier independently developed by the company.
-
The State Food and Drug Administration and the Center for Drug Evaluation issued 4 guiding principles related to traditional Chinese medicine
Time of Update: 2022-01-26
On January 7, the State Food and Drug Administration issued the "Technical Guidelines for Revision of Safety Information Items in the Instruction Sheet of Listed Chinese Medicines (Trial)", and CDE issued "Guidelines for Compiling Traditional Chinese Medicine Theory Application Materials for New Chinese Medicine Compound Preparations (Trial)" and other 3 items guiding principles .
-
The policy spring breeze is blowing all over the ground. Is the future of traditional Chinese medicine really beautiful?
Time of Update: 2022-01-26
Major policies of the Chinese medicine industry in recent years Source: Government website, Zhongkang Industrial Capital Research Center Strengthen medical insurance support On December 30, 2021, the "Guiding Opinions" jointly issued by the National Medical Insurance Administration and the Administration of Traditional Chinese Medicine promoted the reform of traditional Chinese medicine from the aspects of terminal coverage, pricing system, and payment system .
-
Enterprises need to pay attention to these five points that the centralized procurement of Chinese patent medicines in Hubei has far-reaching influence!
Time of Update: 2022-01-26
The bidding results of the centralized procurement of Chinese patent medicines of the 19-province alliance of Hubei have been announced.
The bidding results of the centralized procurement of Chinese patent medicines of the 19-province alliance of Hubei have been announced.
-
The prospects of the pharmaceutical equipment industry are optimistic, and many stocks such as Chutian Technology rose
Time of Update: 2022-01-26
On the news of the pharmaceutical equipment industry (photo source: Pharmaceutical Network), on January 6, Chutian Technology issued an announcement saying that the company reviewed and approved the "Regulations on Granting Partially Reserved Restricted Stocks to Incentive Objects" on January 5, 2022.
-
In 2022, the six major tracks of the pharmaceutical sector will have a high degree of prosperity
Time of Update: 2022-01-26
On the one hand, the global innovative drug projects in the clinical stage are accelerating, the demand for CDMO will continue to grow, and overseas orders will continue to be transferred to China, bringing huge market opportunities to domestic enterprises; on the other hand, with the API + preparations With the advancement of CDMO's integrated layout, the revenue generated by a single project is also expected to increase .
-
Announcement of R&D expenses of 71 pharmaceutical companies: Yiling, Baiyunshan, China Resources Sanjiu...
Time of Update: 2022-01-26
Image source: WeChat public account "Pharmaceutical Aspects"Relevant people in the industry believe that according to the current development trend of new traditional Chinese medicines, the market size is expected to exceed one trillion yuan in 2022, and will reach 1.
-
Another new drug in the antitumor drug market has been approved!
Time of Update: 2022-01-26
It is expected in the industry that under this background, the 3 types of generic drugs of Zoledronic acid injection of NBP Pharmaceuticals of CSPC will face very fierce market competition in the future .
-
Junshengtai Appoints Chen Jin as Senior Vice President of Pharmacokinetics and Clinical Pharmacology
Time of Update: 2022-01-26
Chen Jin has served as clinical development director and clinical pharmacology director of Novartis Cardiovascular, Nephrology and Metabolism Business Unit and Chronic Liver Disease Business Unit, and has led the clinical development of a number of new drugs, including the adaptation of Junshengtai's main focus.
